期刊文献+

恶性肿瘤合并静脉血栓30例临床分析 被引量:4

原文传递
导出
摘要 目的探讨恶性肿瘤患者合并静脉血栓栓塞的危险因素、诊断及治疗特点。方法收集我院近8年来收治的30例恶性肿瘤合并血栓栓塞患者为病例组,并收集同期不伴有血栓栓塞的30例恶性肿瘤患者为对照组,回顾性分析临床资料,对栓塞部位、治疗效果进行分析,并对照分析危险因素、D-二聚体水平等。结果病例组30例患者中,下肢深静脉血栓18例、上肢6例,肺栓塞2例、脑栓塞2例,其他2例。7例治愈,8例好转,总有效率50.0%,8例患者积极治疗后3 d内起效。病例组血清D-二聚体水平明显高于对照组(t=2.71,P<0.05)。结论恶性肿瘤并发远处转移、置入中心静脉导管、应用地塞米松时易并发血栓形成。D-二聚体对诊断VTE及判断预后有一定辅助作用,治疗主要采用抗凝、祛聚集等。
作者 何玉明
出处 《中华临床医师杂志(电子版)》 CAS 2013年第23期332-334,共3页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献9

  • 1Korte W. Cancer and thrombosis:an increasingly important association[J].{H}SUPPORTIVE CARE IN CANCER,2008.223-228.
  • 2蔡欣,程艳,王阿曼,刘基巍.恶性肿瘤并发血栓栓塞61例临床分析[J].临床肿瘤学杂志,2011,16(4):349-352. 被引量:21
  • 3Maialo A,Tua A,Grigna IG. Hemostasis and cancer:tumor cells induce the expression of tissue factor-like procoagulant activity on endothelia cell[J].{H}HAEMATOLOGICA,2002.624-628.
  • 4Caine GJ,Stonelake PS,Lip GY. The hypercoagulable state of malignancy:pathogenesis and current debate[J].{H}Neoplasia,2002.465-473.
  • 5林莉,徐建明,王岩,刘建芝,李志强,刘烈军,赵传华,葛飞娇,李珊珊.恶性肿瘤合并静脉血栓形成35例临床研究[J].临床肿瘤学杂志,2010,15(2):153-156. 被引量:21
  • 6李国,陆慰萱,王辰.恶性肿瘤合并肺栓塞60例临床分析[J].中华肿瘤杂志,2009,31(7):550-553. 被引量:23
  • 7Blom JW,Doggen CJ,Osamto S. Malignancies,prothrombotic mutations,and the risk of venous thrombosis[J].TAMA,2005.715-722.
  • 8Alikhan R,Cohen A,Combe S. Risk factors of venous thromboembolism in hospitalized patients with acute medical illness[J].{H}Archives of Internal Medicine,2004.963-968.
  • 9Khorana AA. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease:strategies for improving VTE prophylaxis in hospitalized cancer patients[J].{H}Oncologist(the)t,2007.1361-1370.

二级参考文献27

  • 1陆慰萱.第13届血栓栓塞症国际研讨会纪要[J].中华内科杂志,2006,45(12):1035-1036. 被引量:8
  • 2Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline : recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol, 2007, 25:5490-5505.
  • 3Caine GJ, Stonelake PS, Lip GY, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia, 2002, 4:465-473.
  • 4Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med, 2007, 13:362-367.
  • 5Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 2005, 293 : 715-722.
  • 6Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition ). Chest, 2008, 133 (6 suppl) :381S-453S.
  • 7Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. The Oncologist, 2004, 9:207-216.
  • 8Monreala M, Trujillo-Santos J. Screening for occult cancer in patients with acute venous thromboembolism. Curr Opin Pulm Med, 2007, 13:368-371.
  • 9Khorana AA. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease : strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist, 2007, 12 : 1361-1370.
  • 10Baron JA, Gridley G, Weiderpass E, et al. Venous thromboemlolsim and cancer[J]. Lancet, 1998,351:9109.

共引文献59

同被引文献61

引证文献4

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部